Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
| ▸ | FOXM1 | Q08050 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763835 | 0.91 | ESR1 (0.34) | ESR1MAPTNPSR1SLC6A3SLC6A4 | |
| SCHEMBL10199844 | 0.84 | PKM (0.39) | ESR1MAPTNPSR1 | |
| SCHEMBL2626926 | 0.84 | MAPT (0.38) | MAPTNPSR1SLC6A3SLC6A4ALDH1A1 | |
| SCHEMBL29030455 | 0.83 | ESR1 (0.38) | ESR1FOXM1MGLLCA12CA1 | |
| SCHEMBL29030456 | 0.83 | ESR1 (0.38) | ESR1FOXM1MGLLCA12CA1 | |
| SCHEMBL7524110 | 0.83 | RECQL (0.43) | ESR1ALDH1A1 | |
| SCHEMBL19204564 | 0.83 | ESR1 (0.38) | ESR1FOXM1MGLLCA12CA1 | |
| SCHEMBL13892546 | 0.81 | ALDH1A1 (0.36) | ESR1FOXM1ALDH1A1CYP3A4TSHR | |
| SCHEMBL25519028 | 0.79 | ESR1 (0.40) | ESR1CYP1A2 | |
| SCHEMBL8854606 | 0.79 | ESR1 (0.52) | ESR1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116410064-A | Method for synthesizing 2- (alpha-methoxy-3-hydroxy benzylidene) adamantane compound | 西安交通大学 | 2023-07-11 | — | — | CN | disclosed |
| US-10031142-B2 | In situ chemiluminescent substrates and assays | Life Technologies Corporation (US) | 2018-07-24 | — | — | US | disclosed |
| US-10031142-B2 | In situ chemiluminescent substrates and assays | Life Technologies Corporation (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2590958-B1 | IN SITU CHEMILUMINESCENT SUBSTRATES AND ASSAYS | LIFE TECHNOLOGIES CORP (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20130196325-A1 | In Situ Chemiluminescent Substrates and Assays | Life Technologies Corporation (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196325-A1 | In Situ Chemiluminescent Substrates and Assays | Life Technologies Corporation (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2012006351-A1 | IN SITU CHEMILUMINESCENT SUBSTRATES AND ASSAYS | Life Technologies Corporation (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10031142-B2 | In situ chemiluminescent substrates and assays | DNASE1L3, DCLRE1B, RNASE1 | ESR1 1803/4885MAPT 4533/4885NPSR1 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.